Volume 13, Number 8—August 2007
Research
Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission
Table 1
Potential predictor | No. ESBL colonized (n = 117) | No. not ESBL colonized (n = 5,092) | p value† |
---|---|---|---|
Age, y (median, IQR) | 62 (49–71) | 56 (45–67) | <0.01 |
CDS (median, IQR) | 8 (5–10) | 8 (5–10) | 0.20 |
CDS-ID (median, IQR) | 3.21 (1.83–4.78) | 2.83 (1.83–3.40) | <0.01 |
Sex, female, no. (%) | 59 (50) | 2,311 (45) | 0.30 |
Antimicrobial drug exposures, no. (%)‡ | |||
Quinolone | 18 (15) | 617 (12) | 0.32 |
1st-generation cephalosporin | 9 (8) | 559 (11) | 0.30 |
3rd-generation cephalosporin | 7 (6) | 293 (6) | 0.84 |
Vancomycin | 34 (29) | 616 (12) | <0.01 |
Aminoglycoside | 11 (9) | 366 (7) | 0.36 |
Piperacillin-tazobactam | 50 (43) | 1,090 (21) | <0.01 |
Cefepime | 9 (8) | 161 (3) | 0.01 |
Imipenem | 11 (9) | 224 (4) | 0.02 |
*ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; IQR, interquartile range; CDS, Chronic Disease Score; CDS-ID, infectious disease–specific CDS.
†Fisher exact test for dichotomous predictors and Wilcoxon test for continuous predictors.
‡Antimicrobial drug exposures that occurred during the index hospital admission but before ICU admission.
Page created: June 30, 2010
Page updated: June 30, 2010
Page reviewed: June 30, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.